Halozyme Therapeutics Inc (HALO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Helen I. Torley
Employees:
390
11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA 92121-1345
(858) 794-8889

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company. Its products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

Data derived from most recent annual or quarterly report
Market Cap 4.4 Billion Shares Outstanding135.415 Million Avg 30-day Volume 1.187 Million
P/E Ratio28.9943 Dividend Yield0.0 EPS1.33
Price to Revenue7.4703 Debt to Equity22.6937 EBITDA326.861 Million
Price to Book Value79.9757 Operating Margin34.8468 Enterprise Value6.485 Billion
Current Ratio6.691 EPS Growth-0.564 Quick Ratio5.119
1 Yr BETA 0.7163 52-week High/Low 59.46 / 29.85 Profit Margin25.7647
Operating Cash Flow Growth-3.3446 Altman Z-Score3.2565 Free Cash Flow to Firm -736.072 Million
Earnings Report2023-08-08

Are you looking for this stock instead?

View SEC Filings from HALO instead.

View recent insider trading info

Halozyme Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding HALO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding HALO

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-05-09 by POSARD MATTHEW L.
  • 4: filed on 2023-05-09 by MIYASHITA AKIKO MONI
  • 4: filed on 2023-05-09 by MATSUI CONNIE
  • 4: filed on 2023-05-09 by HENDERSON JEFFREY WILLIAM
  • 4: filed on 2023-05-09 by DUNCAN BARBARA GAYLE
  • 4: filed on 2023-05-09 by DALY JAMES M
  • 4: filed on 2023-05-09 by CONNAUGHTON BERNADETTE
  • 4: filed on 2023-05-09 by BIZZARI JEAN-PIERRE
  • 4: filed on 2023-04-19 by LABARRE MICHAEL J.
  • 4/A: filed on 2023-04-19 by LABARRE MICHAEL J.

    • Events (8k)

  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-08:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-03-16:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-13:
    Item 8.01: Other Events
  • 8-K: filed on 2023-02-23:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-02-21:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-02-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
  • 8-K: filed on 2023-01-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-19:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

  • 144: filed on 2023-04-18:

    • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    10 Thousand total shares from 1 transactions

    Exercise Derivative Conversion (M)

    10 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    MATSUI CONNIE

    • Director
    		 187,004 2023-05-05 2

    HENDERSON JEFFREY WILLIAM

    • Director
    		 47,110 2023-05-05 2

    DUNCAN BARBARA GAYLE

    • Director
    		 9,253 2023-05-05 3

    POSARD MATTHEW L.

    • Director
    		 113,254 2023-05-05 2

    DALY JAMES M

    • Director
    		 40,503 2023-05-05 1

    MIYASHITA AKIKO MONI

    • Director
    		 14,271 2023-05-05 1

    BIZZARI JEAN-PIERRE

    • Director
    		 66,815 2023-05-05 1

    CONNAUGHTON BERNADETTE

    • Director
    		 40,286 2023-05-05 2

    LABARRE MICHAEL J. SVP, CHIEF TECHNICAL OFFICER

    • Officer
    		 141,911 2023-04-18 9

    TORLEY HELEN PRESIDENT AND CEO

    • Officer
    • Director
    		 623,666 2023-03-07 9

    SNYDER MARK HOWARD SVP, GENERAL COUNSEL

    • Officer
    		 0 2023-02-16 2

    LABROSSE NICOLE SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 9,066 2023-02-16 4

    MATSUDA MASARU SVP, GENERAL COUNSEL

    • Officer
    		 26,932 2021-09-04 0

    KELLEY KENNETH J

    • Director
    		 179,833 2021-04-14 0

    SUN ELAINE D SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 44,618 2021-04-01 0

    STELZER LAURIE SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 126,167 2020-02-22 0

    HICKEY BENJAMIN SVP, CHIEF COMMERICAL OFFICER

    • Officer
    		 13,226 2019-10-01 0

    CHONDROS DIMITRIOS SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 38,584 2019-08-03 0

    ARMOUR ALISON A. SVP, RESEARCH & DEVELOPMENT

    • Officer
    		 0 2019-06-03 0

    LEONHARDT HARRY J SVP, GC

    • Officer
    		 66,373 2019-04-13 0

    KIRK RANDAL J

    • 10% Owner
    		 No longer subject to file 2018-08-24 0

    GERGEN MARK J SVP, CHIEF OPERATING OFFICER

    • Officer
    		 0 2017-02-22 0

    COUNTOURIOTIS ATHENA SVP AND CHIEF MEDICAL OFFICER

    • Officer
    		 0 2017-02-22 0

    FALBERG KATHRYN E

    • Director
    		 358,253 2016-05-04 0

    RAMSAY DAVID A VP AND CHIEF FINANCIAL OFFICER

    • Officer
    		 364,320 2015-02-04 0

    PATTON JOHN STUART

    • Director
    		 179,876 2014-08-19 0

    ENGLER ROBERT

    • Director
    		 273,176 2014-08-14 0

    LIU JEAN I VP & GENERAL COUNSEL

    • Officer
    		 0 2014-02-06 0

    SHAFFER JAMES P VP & CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2014-02-06 0

    FROST GREGORY IAN CEO, PRESIDENT

    • Officer
    • Director
    		 3,641,380 2013-12-11 0

    SHEPARD H. MICHAEL VP, CHIEF SCIENTIFIC OFFICER

    • Officer
    		 13,198 2013-08-19 0

    GUSTAFSON KURT A VICE PRESIDENT AND CFO

    • Officer
    		 0 2013-02-04 0

    FALLON WILLIAM J VP, MANUFACTURING & OPERATIONS

    • Officer
    		 0 2011-05-10 0

    LITTLE ROBERT J VP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2010-02-04 0

    LIM JONATHAN E CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2010-02-04 0

    LEFF JONATHAN A VP, CHIEF MEDICAL OFFICER

    • Officer
    		 0 2009-08-06 0

    THORNTON STEVEN T

    • Director
    		 30,000 2008-05-08 0

    YOCUM RICHARD C VP-CLINICAL DEVELOPMENT

    • Officer
    		 0 2008-02-06 0

    HOOPER MATTHEW VICE PRES & GENERAL COUNSEL

    • Officer
    		 125,000 2007-11-12 0

    KENNARD DON A VICE PRESIDENT, REGULATORY AFF

    • Officer
    		 0 2007-05-23 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    DUNCAN BARBARA GAYLE - Director

    		2023-05-09 18:16:24 -0400 2023-05-05 A 8,065 a 9,253 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    POSARD MATTHEW L. - Director

    		2023-05-09 18:27:10 -0400 2023-05-05 A 11,371 a 11,371 direct

    POSARD MATTHEW L. - Director

    		2023-05-09 18:27:10 -0400 2023-05-05 A 8,065 a 113,254 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    MIYASHITA AKIKO MONI - Director

    		2023-05-09 18:24:04 -0400 2023-05-05 A 11,371 a 11,371 direct

    MIYASHITA AKIKO MONI - Director

    		2023-05-09 18:24:04 -0400 2023-05-05 A 8,065 a 14,271 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    MATSUI CONNIE - Director

    		2023-05-09 18:21:33 -0400 2023-05-05 A 11,371 a 11,371 direct

    MATSUI CONNIE - Director

    		2023-05-09 18:21:33 -0400 2023-05-05 A 8,065 a 187,004 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    HENDERSON JEFFREY WILLIAM - Director

    		2023-05-09 18:19:02 -0400 2023-05-05 A 11,371 a 11,371 direct

    HENDERSON JEFFREY WILLIAM - Director

    		2023-05-09 18:19:02 -0400 2023-05-05 A 8,065 a 47,110 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    DUNCAN BARBARA GAYLE - Director

    		2023-05-09 18:16:24 -0400 2023-05-05 A 11,371 a 11,371 direct

    DALY JAMES M - Director

    		2023-05-09 18:14:01 -0400 2023-05-05 A 11,371 a 11,371 direct

    DALY JAMES M - Director

    		2023-05-09 18:14:01 -0400 2023-05-05 A 8,065 a 40,503 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    CONNAUGHTON BERNADETTE - Director

    		2023-05-09 18:12:04 -0400 2023-05-05 A 11,371 a 11,371 direct

    CONNAUGHTON BERNADETTE - Director

    		2023-05-09 18:12:04 -0400 2023-05-05 A 8,065 a 40,286 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    BIZZARI JEAN-PIERRE - Director

    		2023-05-09 18:09:24 -0400 2023-05-05 A 11,371 a 11,371 direct

    BIZZARI JEAN-PIERRE - Director

    		2023-05-09 18:09:24 -0400 2023-05-05 A 8,065 a 66,815 direct -4.3491 -2.9864 0.0 1 -4.3781 3

    LABARRE MICHAEL J. - Officer SVP, CHIEF TECHNICAL OFFICER

    		2023-04-19 18:07:35 -0400 2023-04-18 M 10,000 $18.41 a 151,911 direct yes 1.0914 -4.8968 1.0914 2 -4.8968 6

    LABARRE MICHAEL J. - Officer SVP, CHIEF TECHNICAL OFFICER

    		2023-04-19 18:07:35 -0400 2023-04-18 M 10,000 d 27,505 direct yes

    LABARRE MICHAEL J. - Officer SVP, CHIEF TECHNICAL OFFICER

    		2023-04-19 18:07:35 -0400 2023-04-18 S 10,000 $36.00 d 141,911 direct yes 1.0914 -4.8968 1.0914 2 -4.8968 6

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 22:15:04 UTC 4.7904 0.2696 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 21:45:04 UTC 4.7904 0.2696 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 21:15:04 UTC 4.7913 0.2687 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 20:45:03 UTC 4.7913 0.2687 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 20:15:05 UTC 4.7913 0.2687 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 19:45:04 UTC 4.7913 0.2687 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 19:15:04 UTC 4.7913 0.2687 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 18:45:04 UTC 4.7903 0.2697 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 18:15:04 UTC 4.7903 0.2697 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 17:45:03 UTC 4.7903 0.2697 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 17:15:04 UTC 4.7903 0.2697 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 16:45:03 UTC 4.8018 0.2682 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 16:15:04 UTC 4.8018 0.2682 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 15:45:04 UTC 4.8018 0.2682 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 15:15:03 UTC 4.8018 0.2682 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 14:45:04 UTC 4.8018 0.2682 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 14:15:03 UTC 4.8018 0.2682 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 13:45:03 UTC 4.82 0.25 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 13:15:04 UTC 4.82 0.25 4200000
    HALOZYME THERAPEUTICS INC HALO 2023-06-02 12:45:03 UTC 4.82 0.25 4200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    FundVantage Trust- Gotham Index Plus All-Cap Fund HALO -11.0 shares, $-197.89 2020-03-31 N-PORT
    Morningstar Funds Trust- Morningstar Alternatives Fund HALO -6369.0 shares, $-329723.13 2023-01-31 N-PORT
    Calamos Investment Trust/IL- Calamos Market Neutral Income Fund HALO -460224.0 shares, $-23825796.48 2023-01-31 N-PORT
    Franklin Alternative Strategies Funds- K2 Alternative Strategies Fund HALO -4426.0 shares, $-212403.74 2023-02-28 N-PORT
    Guidestone Funds- Strategic Alternatives Fund HALO -2080.0 shares, $-79435.2 2023-03-31 N-PORT
    AMERICAN BEACON FUNDS- American Beacon SSI Alternative Income Fund HALO -6568.0 shares, $-250831.92 2023-03-31 N-PORT
    VANGUARD MONTGOMERY FUNDS- VANGUARD MARKET NEUTRAL FUND HALO -90235.0 shares, $-3446074.65 2023-03-31 N-PORT
    FORUM FUNDS- ABSOLUTE CONVERTIBLE ARBITRAGE FUND HALO -106500.0 shares, $-4067235.0 2023-03-31 N-PORT

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Josh Gottheimer democrat House Filing 2023-01-04 2022-12-06 JT SP $1,001-$15,000

    Elevate your investments